Section 12 · Monograph
Eplontersen
Reviewed Nov 2026FDA label
WainuaAntisense oligonucleotide (TTR)
- Forms
- SC autoinjector or prefilled syringe: 45mg/0.8mL
- Dose
- 45mg SC once monthly
- MOA
- Degrades TTR mRNA, ↓hepatic TTR production
Indications
- Polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adultsFDA-labeled
Mechanism of Action
- Ligand-conjugated antisense oligonucleotide targeting TTR mRNA in hepatocytes, reducing TTR protein production
Full Dosing
Adult / usual
- 45mg by subcutaneous injection once monthly into the abdomen or upper thigh (back of upper arm if given by a healthcare provider or caregiver); autoinjector or prefilled syringe
- Missed dose: give as soon as possible and resume monthly from that date
- Vitamin A supplementation at the recommended daily allowance
Contraindications
- None listed in labeling
Drug Interactions
- No drug interactions identified in the prescribing information
Adverse Effects
- Decreased vitamin A (about 15%)
- Vomiting (about 9%)
- Injection-site reactions
Monitoring Parameters
- Ocular symptoms of vitamin A deficiency
- Neuropathy assessment
Pregnancy & Lactation
- No human data; reduced vitamin A could harm the fetus — weigh risk and benefit
- No information on presence in human milk